Imunon(IMNN) - 2024 Q4 - Annual Results

Exhibit 99.1 IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in Q1 2025 Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) – IMUNON, Inc. (NASDAQ: IMNN), a clini ...